Related Experiment Video

Updated: May 11, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Andrographis restrains the progression of colorectal cancer by inhibiting the KLF3/LEMD1 axis

Leyi Zhang1, Dongyang Li2, Yan Tang2

  • 1Department of General Surgery, Chun'an First People's Hospital (Zhejiang Provincial People's Hospital Chun'an Branch), Hangzhou, China.

Functional & Integrative Genomics
|May 9, 2026
PubMed

Insights

Andrographis shows anti-cancer effects in colorectal cancer by reducing LEM domain containing 1 (LEMD1) and Krüppel-like factor 3 (KLF3) expression, inhibiting tumor growth and spread.

Area of Science:

  • Oncology
  • Molecular Biology
  • Natural Product Chemistry

Background:

  • Andrographis possesses known anti-cancer properties, particularly against colorectal cancer.
  • Understanding the precise molecular mechanisms of Andrographis in colorectal cancer is crucial for therapeutic development.

Purpose of the Study:

  • To elucidate the detailed mechanisms by which Andrographis inhibits colorectal cancer progression.
  • To investigate the roles of LEM domain containing 1 (LEMD1) and Krüppel-like factor 3 (KLF3) in Andrographis's anti-tumor effects.

Main Methods:

  • Cell proliferation, invasion, and apoptosis assays were performed on colorectal cancer cell lines (LoVo and HCT-116).
  • Gene expression analysis was conducted for LEMD1 and KLF3.
  • In vivo studies utilized colorectal cancer mouse models to assess tumor growth and molecular changes.

Main Results:

  • Andrographis significantly inhibited proliferation, invasion, and induced apoptosis in colorectal cancer cells.
  • Andrographis downregulated the expression of LEM domain containing 1 (LEMD1) and Krüppel-like factor 3 (KLF3).
  • LEMD1 knockdown mimicked Andrographis's anti-tumor effects, while KLF3 overexpression reversed them, indicating KLF3 targets LEMD1.

Conclusions:

  • Andrographis exerts anti-cancer effects in colorectal cancer by suppressing the KLF3-LEMD1 signaling pathway.
  • Targeting KLF3 and LEMD1 represents a potential therapeutic strategy for colorectal cancer treatment using Andrographis.
Keywords:
AndrographisColorectal cancerKLF3LEMD1

More Related Videos

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine06:24

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...